Diquat may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Benzalkonium chloride (a derivative of Benzalkonium) is reported as an ingredient of Diquat in the following countries:
International Drug Name Search
Epinefrina Dany may be available in the countries listed below.
Epinephrine is reported as an ingredient of Epinefrina Dany in the following countries:
International Drug Name Search
Durnit may be available in the countries listed below.
Zolpidem tartrate (a derivative of Zolpidem) is reported as an ingredient of Durnit in the following countries:
International Drug Name Search
Belgest may be available in the countries listed below.
Progesterone is reported as an ingredient of Belgest in the following countries:
International Drug Name Search
Sintemicina may be available in the countries listed below.
Mitomycin is reported as an ingredient of Sintemicina in the following countries:
International Drug Name Search
Clatic may be available in the countries listed below.
Clarithromycin is reported as an ingredient of Clatic in the following countries:
International Drug Name Search
Bearoxyl may be available in the countries listed below.
Cefadroxil is reported as an ingredient of Bearoxyl in the following countries:
International Drug Name Search
Limbron may be available in the countries listed below.
Midodrine is reported as an ingredient of Limbron in the following countries:
International Drug Name Search
A-B1 may be available in the countries listed below.
Thiamine is reported as an ingredient of A-B1 in the following countries:
International Drug Name Search
Maalox maux d'estomac may be available in the countries listed below.
Aluminium Hydroxide is reported as an ingredient of Maalox maux d'estomac in the following countries:
Magnesium Hydroxide is reported as an ingredient of Maalox maux d'estomac in the following countries:
International Drug Name Search
Butamben Picrate may be available in the countries listed below.
Butamben Picrate (USAN) is known as Butamben in the US.
International Drug Name Search
Glossary
| USAN | United States Adopted Name |
Rinoster may be available in the countries listed below.
Budesonide is reported as an ingredient of Rinoster in the following countries:
International Drug Name Search
Tretinac may be available in the countries listed below.
Isotretinoin is reported as an ingredient of Tretinac in the following countries:
International Drug Name Search
Biomicina may be available in the countries listed below.
Fosfomycin is reported as an ingredient of Biomicina in the following countries:
International Drug Name Search
Anwu may be available in the countries listed below.
Fluvoxamine maleate (a derivative of Fluvoxamine) is reported as an ingredient of Anwu in the following countries:
International Drug Name Search
Alizar may be available in the countries listed below.
Clobetasol is reported as an ingredient of Alizar in the following countries:
Spironolactone is reported as an ingredient of Alizar in the following countries:
International Drug Name Search
This is a powerful fluid-reducing medicine. Using too much of Bumex can lead to serious water and mineral loss. Therefore, it is important that you be monitored by your doctor. Tell your doctor right away if you become very thirsty, have dry mouth, become confused, or develop muscle cramps/weakness.
Treating swelling caused by excess body water associated with heart failure or kidney or liver disease. It may also be used for other conditions as determined by your doctor.
Bumex is a loop diuretic. It works by forcing the kidney to eliminate sodium, potassium, and water.
Contact your doctor or health care provider right away if any of these apply to you.
Tell your health care provider if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with Bumex. Tell your health care provider if you are taking any of the following medicines.
This may not be a complete list of all interactions that may occur. Ask your health care provider if Bumex may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use Bumex as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Bumex.
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Dizziness or lightheadedness when sitting up or standing; drowsiness; headache; low blood pressure.
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); confusion; diarrhea; extreme thirst or dry mouth; loss of appetite; muscle cramps; nausea; pain, redness, or swelling at injection site; rapid or irregular heartbeat; red, blistered, swollen, or peeling skin; ringing in the ears or hearing loss; stomach cramps; weakness; vomiting.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
See also: Bumex side effects (in more detail)
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include dizziness; dry mouth; excessive urination followed by a decrease in amount of urine; muscle cramps; weak or irregular heartbeat; weakness.
Store Bumex at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Bumex, as well as needles and syringes, out of the reach of children and away from pets.
This information is a summary only. It does not contain all information about Bumex. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
Neurostil may be available in the countries listed below.
Gabapentin is reported as an ingredient of Neurostil in the following countries:
International Drug Name Search
In the US, Vorinostat (vorinostat systemic) is a member of the drug class histone deacetylase inhibitors and is used to treat Cutaneous T-cell Lymphoma.
US matches:
Rec.INN
L01XX38
0149647-78-9
C14-H20-N2-O3
264
Anti-inflammatory agent
Antineoplastic agent
Enzyme inhibitor
N-hydroxy-N'-phenyloctanediamide (WHO)
Korksäure-anilid-Hydroxamsäure
Octandisäure hydroxyamid phenylamid (IUPAC)
Octanediamide, N-hydroxy-N'-phenyl-
Suberoylanilide hydroxamic acid
International Drug Name Search
Glossary
| IUPAC | International Union of Pure and Applied Chemistry |
| IS | Inofficial Synonym |
| OS | Official Synonym |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| USAN | United States Adopted Name |
| WHO | World Health Organization |
Biodicaine may be available in the countries listed below.
Cetrimide is reported as an ingredient of Biodicaine in the following countries:
Lidocaine is reported as an ingredient of Biodicaine in the following countries:
International Drug Name Search
Cetonax may be available in the countries listed below.
Ketoconazole is reported as an ingredient of Cetonax in the following countries:
International Drug Name Search
Rolap may be available in the countries listed below.
Tamoxifen citrate (a derivative of Tamoxifen) is reported as an ingredient of Rolap in the following countries:
International Drug Name Search
Pacimol may be available in the countries listed below.
Paracetamol is reported as an ingredient of Pacimol in the following countries:
International Drug Name Search
Mednap may be available in the countries listed below.
Naproxen sodium salt (a derivative of Naproxen) is reported as an ingredient of Mednap in the following countries:
International Drug Name Search
Bidinatec may be available in the countries listed below.
Enalapril is reported as an ingredient of Bidinatec in the following countries:
International Drug Name Search
NovoRapid may be available in the countries listed below.
UK matches:
Insulin Aspart is reported as an ingredient of NovoRapid in the following countries:
International Drug Name Search
Glossary
| SPC | Summary of Product Characteristics (UK) |
Rhinos Neo may be available in the countries listed below.
Pseudoephedrine hydrochloride (a derivative of Pseudoephedrine) is reported as an ingredient of Rhinos Neo in the following countries:
International Drug Name Search
Niberan may be available in the countries listed below.
Nimesulide is reported as an ingredient of Niberan in the following countries:
International Drug Name Search
Linkomed may be available in the countries listed below.
Lincomycin is reported as an ingredient of Linkomed in the following countries:
International Drug Name Search
Oxazepam Sandoz may be available in the countries listed below.
Oxazepam is reported as an ingredient of Oxazepam Sandoz in the following countries:
International Drug Name Search
Quinapril EG may be available in the countries listed below.
Quinapril is reported as an ingredient of Quinapril EG in the following countries:
Quinapril hydrochloride (a derivative of Quinapril) is reported as an ingredient of Quinapril EG in the following countries:
International Drug Name Search
Zycin may be available in the countries listed below.
Azithromycin is reported as an ingredient of Zycin in the following countries:
International Drug Name Search
Pantomucol may be available in the countries listed below.
Erythromycin is reported as an ingredient of Pantomucol in the following countries:
International Drug Name Search
Ranoprin may be available in the countries listed below.
Propranolol hydrochloride (a derivative of Propranolol) is reported as an ingredient of Ranoprin in the following countries:
International Drug Name Search
UK matches:
Bisoprolol Fumarate (BANM, USAN) is known as Bisoprolol in the US.
International Drug Name Search
Glossary
| BANM | British Approved Name (Modified) |
| SPC | Summary of Product Characteristics (UK) |
| USAN | United States Adopted Name |
Spasmag may be available in the countries listed below.
Magnesium Sulfate is reported as an ingredient of Spasmag in the following countries:
International Drug Name Search
In the US, Bedol is a member of the drug class estrogens and is used to treat Postmenopausal Symptoms.
UK matches:
Estradiol is reported as an ingredient of Bedol in the following countries:
International Drug Name Search
Glossary
| SPC | Summary of Product Characteristics (UK) |
Bisoprolol fumarate tablets USP (Bisoprolol fumarate) is a synthetic, beta1-selective (cardioselective) adrenoceptor blocking agent. The chemical name for Bisoprolol fumarate USP is (±) - 1 - [4 - [[2 - (1 - Methylethoxy)ethoxy]methyl]phenoxy] - 3 - [(1 - methylethyl)amino] - 2 - propanol(E) - 2 - butenedioate (2:1) (salt). It possesses an asymmetric carbon atom in its structure and is provided as a racemic mixture. The S(-) enantiomer is responsible for most of the beta-blocking activity. Its empirical formula is (C18H31NO4)2•C4H4O4 and its structure is:
(C18H31NO4)2•C4H4O4 M.W. 766.96
Bisoprolol fumarate has a molecular weight of 766.96. It is a white crystalline powder which is approximately equally hydrophilic and lipophilic, and is readily soluble in water, methanol, ethanol, and chloroform.
Bisoprolol fumarate tablets USP are available as 5 mg and 10 mg tablets for oral administration.
The tablets contain the following inactive ingredients: colloidal silicon dioxide, corn starch, dibasic calcium phosphate anhydrous, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate and titanium dioxide. In addition, the 5 mg tablets contain FD&C yellow No. 6 aluminum lake and FD&C red No. 40 aluminum lake.
Bisoprolol fumarate is a beta1-selective (cardioselective) adrenoceptor blocking agent without significant membrane stabilizing activity or intrinsic sympathomimetic activity in its therapeutic dosage range. Cardioselectivity is not absolute, however, and at higher doses (≥ 20 mg) Bisoprolol fumarate also inhibits beta2-adrenoceptors, chiefly located in the bronchial and vascular musculature; to retain selectivity it is therefore important to use the lowest effective dose.
The absolute bioavailability after a 10 mg oral dose of Bisoprolol fumarate is about 80%. Absorption is not affected by the presence of food. The first pass metabolism of Bisoprolol fumarate is about 20%.
Binding to serum proteins is approximately 30%. Peak plasma concentrations occur within 2 to 4 hours of dosing with 5 mg to 20 mg, and mean peak values range from 16 ng/mL at 5 mg to 70 ng/mL at 20 mg. Once daily dosing with Bisoprolol fumarate results in less than twofold intersubject variation in peak plasma levels. The plasma elimination half-life is 9 to 12 hours and is slightly longer in elderly patients, in part because of decreased renal function in that population. Steady state is attained within 5 days of once daily dosing. In both young and elderly populations, plasma accumulation is low; the accumulation factor ranges from 1.1 to 1.3, and is what would be expected from the first order kinetics and once daily dosing. Plasma concentrations are proportional to the administered dose in the range of 5 mg to 20 mg. Pharmacokinetic characteristics of the two enantiomers are similar.
Bisoprolol fumarate is eliminated equally by renal and non-renal pathways with about 50% of the dose appearing unchanged in the urine and the remainder appearing in the form of inactive metabolites. In humans, the known metabolites are labile or have no known pharmacologic activity. Less than 2% of the dose is excreted in the feces. Bisoprolol fumarate is not metabolized by cytochrome P450 II D6 (debrisoquin hydroxylase).
In subjects with creatinine clearance less than 40 mL/min, the plasma half-life is increased approximately threefold compared to healthy subjects.
In patients with cirrhosis of the liver, the elimination of Bisoprolol fumarate is more variable in rate and significantly slower than that in healthy subjects, with plasma half-life ranging from 8.3 to 21.7 hours.
The most prominent effect of Bisoprolol fumarate is the negative chronotropic effect, resulting in a reduction in resting and exercise heart rate. There is a fall in resting and exercise cardiac output with little observed change in stroke volume, and only a small increase in right atrial pressure, or pulmonary capillary wedge pressure at rest or during exercise.
Findings in short-term clinical hemodynamics studies with Bisoprolol fumarate are similar to those observed with other beta-blocking agents.
The mechanism of action of its antihypertensive effects has not been completely established. Factors which may be involved include:
1) Decreased cardiac output,
2) Inhibition of renin release by the kidneys,
3) Diminution of tonic sympathetic outflow from the vasomotor centers in the brain.
In normal volunteers, Bisoprolol fumarate therapy resulted in a reduction of exercise- and isoproterenol-induced tachycardia. The maximal effect occurred within 1 to 4 hours post-dosing. Effects persisted for 24 hours at doses equal to or greater than 5 mg.
Electrophysiology studies in man have demonstrated that Bisoprolol fumarate significantly decreases heart rate, increases sinus node recovery time, prolongs AV node refractory periods, and with rapid atrial stimulation, prolongs AV nodal conduction.
Beta1-selectivity of Bisoprolol fumarate has been demonstrated in both animal and human studies. No effects at therapeutic doses on beta2-adrenoceptor density have been observed. Pulmonary function studies have been conducted in healthy volunteers, asthmatics, and patients with chronic obstructive pulmonary disease (COPD). Doses of Bisoprolol fumarate ranged from 5 mg to 60 mg, atenolol from 50 mg to 200 mg, metoprolol from 100 mg to 200 mg, and propranolol from 40 mg to 80 mg. In some studies, slight, asymptomatic increases in airways resistance (AWR) and decreases in forced expiratory volume (FEV1) were observed with doses of Bisoprolol fumarate 20 mg and higher, similar to the small increases in AWR also noted with the other cardioselective beta-blockers. The changes induced by beta-blockade with all agents were reversed by bronchodilator therapy.
Bisoprolol fumarate had minimal effect on serum lipids during antihypertensive studies. In U.S. placebo-controlled trials, changes in total cholesterol averaged +0.8% for Bisoprolol fumarate-treated patients, and +0.7% for placebo. Changes in triglycerides averaged +19% for Bisoprolol fumarate-treated patients, and +17% for placebo.
Bisoprolol fumarate has also been given concomitantly with thiazide diuretics. Even very low doses of hydrochlorothiazide (6.25 mg) were found to be additive with Bisoprolol fumarate in lowering blood pressure in patients with mild-to-moderate hypertension.
Clinical Studies
In two randomized double-blind placebo-controlled trials conducted in the U.S., reductions in systolic and diastolic blood pressure and heart rate 24 hours after dosing in patients with mild-to-moderate hypertension are shown below. In both studies, mean systolic/diastolic blood pressures at baseline were approximately 150/100 mm Hg, and mean heart rate was 76 bpm. Drug effect is calculated by subtracting the placebo effect from the overall change in blood pressure and heart rate.
| ||||
| Study A | Bisoprolol Fumarate | |||
| Placebo | 5 mg | 10 mg | 20 mg | |
| n= | 61 | 61 | 61 | 61 |
| Total ΔBP (mm Hg) | 5.4/3.2 | 10.4/8.0 | 11.2/10.9 | 12.8/11.9 |
| Drug Effect* | - | 5.0/4.8 | 5.8/7.7 | 7.4/8.7 |
| Total ΔHR (bpm) | 0.5 | 7.2 | 8.7 | 11.3 |
| Drug Effect* | - | 6.7 | 8.2 | 10.8 |
| Study B | Bisoprolol Fumarate | |||
| Placebo | 2.5 mg | 10 mg | ||
| n= | 56 | 59 | 62 | |
| Total ΔBP (mm Hg) | 3.0/3.7 | 7.6/8.1 | 13.5/11.2 | |
| Drug Effect* | - | 4.6/4.4 | 10.5/7.5 | |
| Total ΔHR (bpm) | 1.6 | 3.8 | 10.7 | |
| Drug Effect* | - | 2.2 | 9.1 | |
Blood pressure responses were seen within one week of treatment and changed little thereafter. They were sustained for 12 weeks and for over a year in studies of longer duration. Blood pressure returned to baseline when Bisoprolol fumarate was tapered over two weeks in a long-term study.
Overall, significantly greater blood pressure reductions were observed on Bisoprolol fumarate than on placebo regardless of race, age, or gender. There were no significant differences in response between black and non-black patients.
Bisoprolol fumarate tablets USP are indicated in the management of hypertension. It may be used alone or in combination with other antihypertensive agents.
Bisoprolol fumarate is contraindicated in patients with cardiogenic shock, overt cardiac failure, second or third degree AV block, and marked sinus bradycardia.
Sympathetic stimulation is a vital component supporting circulatory function in the setting of congestive heart failure, and beta-blockade may result in further depression of myocardial contractility and precipitate more severe failure. In general, beta-blocking agents should be avoided in patients with overt congestive failure. However, in some patients with compensated cardiac failure it may be necessary to utilize them. In such a situation, they must be used cautiously.
Continued depression of the myocardium with beta-blockers can, in some patients, precipitate cardiac failure. At the first signs or symptoms of heart failure, discontinuation of Bisoprolol fumarate should be considered. In some cases, beta-blocker therapy can be continued while heart failure is treated with other drugs.
Exacerbation of angina pectoris, and in some instances, myocardial infarction or ventricular arrhythmia, have been observed in patients with coronary artery disease following abrupt cessation of therapy with beta-blockers. Such patients should, therefore, be cautioned against interruption or discontinuation of therapy without the physician’s advice. Even in patients without overt coronary artery disease, it may be advisable to taper therapy with Bisoprolol fumarate over approximately one week with the patient under careful observation. If withdrawal symptoms occur, Bisoprolol fumarate therapy should be reinstituted, at least temporarily.
Beta-blockers can precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease. Caution should be exercised in such individuals.
PATIENTS WITH BRONCHOSPASTIC DISEASE SHOULD, IN GENERAL, NOT RECEIVE BETA-BLOCKERS. Because of its relative beta1-selectivity, however, Bisoprolol fumarate may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. Since beta1-selectivity is not absolute, the lowest possible dose of Bisoprolol fumarate should be used, with therapy starting at 2.5 mg. A beta2 agonist (bronchodilator) should be made available.
Chronically administered beta-blocking therapy should not be routinely withdrawn prior to major surgery; however, the impaired ability of the heart to respond to reflex adrenergic stimuli may augment the risks of general anesthesia and surgical procedures.
Beta-blockers may mask some of the manifestations of hypoglycemia, particularly tachycardia. Nonselective beta-blockers may potentiate insulin-induced hypoglycemia and delay recovery of serum glucose levels. Because of its beta1-selectivity, this is less likely with Bisoprolol fumarate. However, patients subject to spontaneous hypoglycemia, or diabetic patients receiving insulin or oral hypoglycemic agents, should be cautioned about these possibilities and Bisoprolol fumarate should be used with caution.
Beta-adrenergic blockade may mask clinical signs of hyperthyroidism, such as tachycardia. Abrupt withdrawal of beta-blockade may be followed by an exacerbation of the symptoms of hyperthyroidism or may precipitate thyroid storm.
Use caution in adjusting the dose of Bisoprolol fumarate in patients with renal or hepatic impairment (see CLINICAL PHARMACOLOGYand DOSAGE AND ADMINISTRATION).
Bisoprolol fumarate should not be combined with other beta-blocking agents. Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of Bisoprolol fumarate may produce excessive reduction of sympathetic activity. In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that Bisoprolol fumarate be discontinued for several days before the withdrawal of clonidine.
Bisoprolol fumarate should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.
Both digitalis glycosides and beta-blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia.
Concurrent use of rifampin increases the metabolic clearance of Bisoprolol fumarate, resulting in a shortened elimination half-life of Bisoprolol fumarate. However, initial dose modification is generally not necessary. Pharmacokinetic studies document no clinically relevant interactions with other agents given concomitantly, including thiazide diuretics and cimetidine. There was no effect of Bisoprolol fumarate on prothrombin time in patients on stable doses of warfarin.
While taking beta-blockers, patients with a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reactions.
Patients, especially those with coronary artery disease, should be warned about discontinuing use of Bisoprolol fumarate without a physician’s supervision. Patients should also be advised to consult a physician if any difficulty in breathing occurs, or if they develop signs or symptoms of congestive heart failure or excessive bradycardia.
Patients subject to spontaneous hypoglycemia, or diabetic patients receiving insulin or oral hypoglycemic agents, should be cautioned that beta-blockers may mask some of the manifestations of hypoglycemia, particularly tachycardia, and Bisoprolol fumarate should be used with caution.
Patients should know how they react to this medicine before they operate automobiles and machinery or engage in other tasks requiring alertness.
Long-term studies were conducted with oral Bisoprolol fumarate administered in the feed of mice (20 and 24 months) and rats (26 months). No evidence of carcinogenic potential was seen in mice dosed up to 250 mg/kg/day or rats dosed up to 125 mg/kg/day. On a body-weight basis, these doses are 625 and 312 times, respectively, the maximum recommended human dose (MRHD) of 20 mg, (or 0.4 mg/kg/day based on a 50 kg individual); on a body-surface-area-basis, these doses are 59 times (mice) and 64 times (rats) the MRHD. The mutagenic potential of Bisoprolol fumarate was evaluated in the microbial mutagenicity (Ames) test, the point mutation and chromosome aberration assays in Chinese hamster V79 cells, the unscheduled DNA synthesis test, the micronucleus test in mice, and the cytogenetics assay in rats. There was no evidence of mutagenic potential in these in vitro and in vivo assays.
Reproduction studies in rats did not show any impairment of fertility at doses up to 150 mg/kg/day of Bisoprolol fumarate, or 375 and 77 times the MRHD on the basis of body-weight and body-surface-area, respectively.
In rats, Bisoprolol fumarate was not teratogenic at doses up to 150 mg/kg/day which is 375 and 77 times the MRHD on the basis of body-weight and body-surface-area, respectively. Bisoprolol fumarate was fetotoxic (increased late resorptions) at 50 mg/kg/day and maternotoxic (decreased food intake and body weight gain) at 150 mg/kg/day. The fetotoxicity in rats occurred at 125 times the MRHD on a body-weight-basis and 26 times the MRHD on the basis of body-surface-area. The maternotoxicity occurred at 375 times the MRHD on a body-weight basis and 77 times the MRHD on the basis of body-surface-area. In rabbits, Bisoprolol fumarate was not teratogenic at doses up to 12.5 mg/kg/day, which is 31 and 12 times the MRHD based on body-weight and body-surface-area, respectively, but was embryolethal (increased early resorptions) at 12.5 mg/kg/day.
There are no adequate and well-controlled studies in pregnant women. Bisoprolol fumarate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Small amounts of Bisoprolol fumarate (<2% of the dose) have been detected in the milk of lactating rats. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk caution should be exercised when Bisoprolol fumarate is administered to nursing women.
Safety and effectiveness in pediatric patients have not been established.
Bisoprolol fumarate has been used in elderly patients with hypertension. Response rates and mean decreases in systolic and diastolic blood pressure were similar to the decreases in younger patients in the U.S. clinical studies. Although no dose response study was conducted in elderly patients, there was a tendency for older patients to be maintained on higher doses of Bisoprolol fumarate.
Observed reductions in heart rate were slightly greater in the elderly than in the young and tended to increase with increasing dose. In general, no disparity in adverse experience reports or dropouts for safety reasons was observed between older and younger patients. Dose adjustment based on age is not necessary.
Safety data are available in more than 30,000 patients or volunteers. Frequency estimates and rates of withdrawal of therapy for adverse events were derived from two U.S. placebo-controlled studies.
In Study A, doses of 5 mg, 10 mg, and 20 mg Bisoprolol fumarate were administered for 4 weeks. In Study B, doses of 2.5 mg, 10 mg, and 40 mg of Bisoprolol fumarate were administered for 12 weeks. A total of 273 patients were treated with 5 mg to 20 mg of Bisoprolol fumarate; 132 received placebo.
Withdrawal of therapy for adverse events was 3.3% for patients receiving Bisoprolol fumarate and 6.8% for patients on placebo. Withdrawals were less than 1% for either bradycardia or fatigue/lack of energy.
The following table presents adverse experiences, whether or not considered drug related, reported in at least 1% of patients in these studies, for all patients studied in placebo-controlled clinical trials (2.5 mg to 40 mg), as well as for a subgroup that was treated with doses within the recommended dosage range (5 mg to 20 mg). Of the adverse events listed in the table, bradycardia, diarrhea, asthenia, fatigue, and sinusitis appear to be dose related.
| |||
| Body System/Adverse Experience | All Adverse Experiences (%*) Bisoprolol Fumarate | ||
| Placebo (n=132) % | 5 mg to 20 mg (n=273) % | 2.5 mg to 40 mg (n=404) % | |
| Skin | |||
| Increased Sweating | 1.5 | 0.7 | 1.0 |
| Musculoskeletal | |||
| Arthralgia | 2.3 | 2.2 | 2.7 |
| Central Nervous System | |||
| Dizziness | 3.8 | 2.9 | 3.5 |
| Headache | 11.4 | 8.8 | 10.9 |
| Hypoaesthesia | 0.8 | 1.1 | 1.5 |
| Autonomic Nervous System | |||
| Dry Mouth | 1.5 | 0.7 | 1.3 |
| Heart Rate/Rhythm | |||
| Bradycardia | 0 | 0.4 | 0.5 |
| Psychiatric | |||
| Vivid Dreams | 0 | 0 | 0 |
| Insomnia | 2.3 | 1.5 | 2.5 |
| Depression | 0.8 | 0 | 0.2 |
| Gastrointestinal | |||
| Diarrhea | 1.5 | 2.6 | 3.5 |
| Nausea | 1.5 | 1.5 | 2.2 |
| Vomiting | 0 | 1.1 | 1.5 |
| Respiratory | |||
| Bronchospasm | 0 | 0 | 0 |
| Cough | 4.5 | 2.6 | 2.5 |
| Dyspnea | 0.8 | 1.1 | 1.5 |
| Pharyngitis | 2.3 | 2.2 | 2.2 |
| Rhinitis | 3.0 | 2.9 | 4.0 |
| Sinusitis | 1.5 | 2.2 | 2.2 |
| URI | 3.8 | 4.8 | 5.0 |
| Body as a Whole | |||
| Asthenia | 0 | 0.4 | 1.5 |
| Chest Pain | 0.8 | 1.1 | 1.5 |
| Fatigue | 1.5 | 6.6 | 8.2 |
| Edema (Peripheral) | 3.8 | 3.7 | 3.0 |
The following is a comprehensive list of adverse experiences reported with Bisoprolol fumarate in worldwide studies, or in postmarketing experience (in italics):
Central Nervous System: Dizziness, unsteadiness, vertigo, syncope, headache, paresthesia, hypoesthesia, hyperesthesia, somnolence, sleep disturbances, anxiety/restlessness, decreased concentration/memory.
Autonomic Nervous System: Dry mouth.
Cardiovascular: Bradycardia, palpitations and other rhythm disturbances, cold extremities, claudication, hypotension, orthostatic hypotension, chest pain, congestive heart failure, dyspnea on exertion.
Psychiatric: Vivid dreams, insomnia, depression.
Gastrointestinal: Gastric/epigastric/abdominal pain, gastritis, dyspepsia, nausea, vomiting, diarrhea, constipation, peptic ulcer.
Musculoskeletal: Muscle/joint pain, arthralgia, back/neck pain, muscle cramps, twitching/tremor.
Skin: Rash, acne, eczema, psoriasis, skin irritation, pruritus, flushing, sweating, alopecia, dermatitis,angioedema, exfoliative dermatitis, cutaneous vasculitis.
Special Senses: Visual disturbances, ocular pain/pressure, abnormal lacrimation, tinnitus, decreased hearing, earache, taste abnormalities.
Metabolic: Gout.
Respiratory: Asthma/bronchospasm, bronchitis, coughing, dyspnea, pharyngitis, rhinitis, sinusitis, URI.
Genitourinary: Decreased libido/impotence, Peyronie’s disease, cystitis, renal colic, polyuria.
Hematologic: Purpura.
General: Fatigue, asthenia, chest pain, malaise, edema, weight gain, angioedema.
In addition, a variety of adverse effects have been reported with other beta-adrenergic blocking agents and should be considered potential adverse effects of Bisoprolol fumarate:
Central Nervous System: Reversible mental depression progressing to catatonia, hallucinations, an acute reversible syndrome characterized by disorientation to time and place, emotional lability, slightly clouded sensorium.
Allergic: Fever, combined with aching and sore throat, laryngospasm, respiratory distress.
Hematologic: Agranulocytosis, thrombocytopenia, thrombocytopenic purpura.
Gastrointestinal: Mesenteric arterial thrombosis, ischemic colitis.
Miscellaneous: The oculomucocutaneous syndrome associated with the beta-blocker practolol has not been reported with Bisoprolol fumarate during investigational use or extensive foreign marketing experience.
In clinical trials, the most frequently reported laboratory change was an increase in serum triglycerides, but this was not a consistent finding.
Sporadic liver test abnormalities have been reported. In the U.S. controlled trials experience with Bisoprolol fumarate treatment for 4 to 12 weeks, the incidence of concomitant elevations in SGOT and SGPT from 1 to 2 times normal was 3.9%, compared to 2.5% for placebo. No patient had concomitant elevations greater than twice normal.
In the long-term, uncontrolled experience with Bisoprolol fumarate treatment for 6 to 18 months, the incidence of one or more concomitant elevations in SGOT and SGPT from 1 to 2 times normal was 6.2%. The incidence of multiple occurrences was 1.9%. For concomitant elevations in SGOT and SGPT of greater than twice normal, the incidence was 1.5%. The incidence of multiple occurrences was 0.3%. In many cases these elevations were attributed to underlying disorders, or resolved during continued treatment with Bisoprolol fumarate.
Other laboratory changes included small increases in uric acid, creatinine, BUN, serum potassium, glucose, and phosphorus and decreases in WBC and platelets. These were generally not of clinical importance and rarely resulted in discontinuation of Bisoprolol fumarate.
As with other beta-blockers, ANA conversions have also been reported on Bisoprolol fumarate. About 15% of patients in long-term studies converted to a positive titer, although about one-third of these patients subsequently reconverted to a negative titer while on continued therapy.
The most common signs expected with overdosage of a beta-blocker are bradycardia, hypotension, congestive heart failure, bronchospasm, and hypoglycemia. To date, a few cases of overdose (maximum: 2000 mg) with Bisoprolol fumarate have been reported. Bradycardia and/or hypotension were noted. Sympathomimetic agents were given in some cases, and all patients recovered.
In general, if overdose occurs, Bisoprolol fumarate therapy should be stopped and supportive and symptomatic treatment should be provided. Limited data suggest that Bisoprolol fumarate is not dialyzable. Based on the expected pharmacologic actions and recommendations for other beta-blockers, the following general measures should be considered when clinically warranted:
Administer IV atropine. If the response is inadequate, isoproterenol or another agent with positive chronotropic properties may be given cautiously. Under some circumstances, transvenous pacemaker insertion may be necessary.
IV fluids and vasopressors should be administered. Intravenous glucagon may be useful.
Patients should be carefully monitored and treated with isoproterenol infusion or transvenous cardiac pacemaker insertion, as appropriate.
Initiate conventional therapy (i.e., digitalis, diuretics, inotropic agents, vasodilating agents).
Administer bronchodilator therapy such as isoproterenol and/or aminophylline.
Administer IV glucose.
The dose of Bisoprolol fumarate tablets must be individualized to the needs of the patient. The usual starting dose is 5 mg once daily. In some patients, 2.5 mg may be an appropriate starting dose (see WARNINGS,Bronchospastic Disease). If the antihypertensive effect of 5 mg is inadequate, the dose may be increased to 10 mg and then, if necessary, to 20 mg once daily.
In patients with hepatic impairment (hepatitis or cirrhosis) or renal dysfunction (creatinine clearance less than 40 mL/min), the initial daily dose should be 2.5 mg and caution should be used in dose-titration. Since limited data suggest that Bisoprolol fumarate is not dialyzable, drug replacement is not necessary in patients undergoing dialysis.
It is not necessary to adjust the dose in the elderly, unless there is also significant renal or hepatic dysfunction (see above and PRECAUTIONS, Geriatric Use).
There is no pediatric experience with Bisoprolol fumarate tablets.
Bisoprolol Fumarate Tablets USP for oral administration are available as:
5 mg: Pink, round, biconvex, film-coated, debossed “E” over “771” and bisected on the other side and supplied as:
NDC 0185-0771-30 bottles of 30
NDC 0185-0771-01 bottles of 100
10 mg: White, round, biconvex, film-coated, debossed “E” over “774” and plain on the other side and supplied as:
NDC 0185-0774-30 bottles of 30
NDC 0185-0774-01 bottles of 100
Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].
Protect from moisture.
Dispense in a tight, light-resistant container as defined in the USP with a child-resistant closure, as required.
KEEP TIGHTLY CLOSED.
KEEP THIS AND ALL MEDICATION OUT OF THE REACH OF CHILDREN.
To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Sandoz Inc.
Princeton, NJ 08540
OS8898
Rev. 12/11
MF0771REV12/11
NDC 0185-0771-30
Bisoprolol Fumarate Tablets USP
5 mg
Rx only
30 Tablets
Sandoz
NDC 0185-0774-30
Bisoprolol Fumarate Tablets USP
10 mg
Rx only
30 Tablets
Sandoz
| Bisoprolol FUMARATE Bisoprolol fumarate tablet, coated | ||||||||||||||||||||||||||
| ||||||||||||||||||||||||||
| ||||||||||||||||||||||||||
| ||||||||||||||||||||||||||
| ||||||||||||||||||||||||||
| ||||||||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| ANDA | ANDA075643 | 11/16/2000 | |
| Bisoprolol FUMARATE Bisoprolol fumarate tab |
In some countries, this medicine may only be approved for veterinary use.
USP
P03AX01
0000120-51-4
C14-H12-O2
212
Scabicide
Benzoic acid, phenylmethyl ester
International Drug Name Search
Glossary
| IS | Inofficial Synonym |
| PH | Pharmacopoeia Name |
| USP | Pharmacopoeia of the United States |
Colcrys is a brand name of colchicine, approved by the FDA in the following formulation(s):
No. There is currently no therapeutically equivalent version of Colcrys available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Colcrys. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
